Scroll to content

Join

Evox Therapeutics was established in 2016 to advance leading edge science from Oxford University and the Karolinska Institute. We work to develop innovative exosome therapeutics for diseases with significant unmet medical need.

Backed by leading venture capital groups and leveraging a comprehensive dominant intellectual property portfolio Evox’s mission is to positively impact human health by creating novel exosome-based therapeutics for the treatment of rare and severe diseases with limited treatment options for patients and their families.

We have already recruited exceptional people working in multidisciplinary teams, sharing our mission to transform how we treat rare diseases. Why not join our team and make your contribution to our journey ahead.

Timeline

Where we started & Where we're going

1981
Cells shed vesicles

Birth of the term 'exosome' through the discovery of shed vesicles from cells.

1983
Multivesicular body formation

First description by Harding et al, of maturing reticulocytes releasing vesicles into the extracellular space

1987
Exosomes described as cell garbage release system
1996
Extracellular communication via vesicles

Landmark discovery by Raposo et al, describing vesicle-meditated transfer of antigens.

2007
Exosomal transfer of genetic material

First of several discoveries describing the transfer of mRNA and miRNA by Evs.

2011
Seminal paper published by one of Evox's founders in Nature Biotechnology

One of the most cited articles in the journal's history, showing that engineered exosomes are capable of delivering siRNA to the brain.

2016
Founded

Founded in Oxford, by Dr. Per Lundin, Professor Matthew Wood, and Dr. Samir El Andaloussi.  The company was spun out from Oxford University and the Karolinska Institute in Sweden.

2016
Series A Fundraising

£10 million raised from Oxford Sciences Innovation.

2017
First two pharma deals signed

Evox entered into two R&D pharma collaborations with global pharmaceutical companies.

2018
Series B Fundraising

£35.5 million raised, bringing new investors into Evox Therapeutics. Redmile Group, Google Ventures, Cowen Healthcare Ventures, Panacea Ventures, and Borealis Ventures. 

2018
Moved into Medawar Lab

Evox moved into the Medawar building.

2019
Innovate UK grant to advance Evox proprietary program to treat a urea cycle disorder.
2020

Takeda and Evox Therapeutics sign multi-target Rare Disease collaboration.

Lilly and Evox Therapeutics announce a multi-target RNAi and antisense research collaboration and license agreement.

Workplace & Culture

At Evox, values are at the heart of how we operate, how we behave, and how we will drive the growth of our exciting company.

We developed the values internally with all our employees, ones which we could all identify and work with.


Our Values

Driven to Deliver
We are ambitious and strive to outperform on timelines and goals with no compromise on quality. We push the boundaries to change what is possible.
Agile and Accountable
We show a flexible mindset in a fast paced environment. We show the ability to flex & respond promptly as required. We are accountable for our actions and take ownership for our deliverables.
People with Purpose
We have pride in our work and our company. We show passion for advancing science which will provide impactful therapeutics to benefit patients.
Candid and Constructive
We are open and transparent in our communication where staff have a voice and are encouraged to express their views candidly and constructively.

Benefits

  • Private Medical Cover

    Cover offered is for new and pre-existing conditions

  • Life Assurance

    Cover offered is 4 x base salary

  • Holidays

    25 days holiday plus bank holidays

  • Pension

    Employer contribution 5%, employee minimum contribution 5%, however, more than 5% can be contributed if you wish

  • Discretionary Bonus

    Bonus is payable based on a combination of corporate and personal performance

  • Evox Stock Options

    Stock Options are issued once the probationary period is passed

Our people love working here

I love working at Evox because of the commitment to excellence, clear vision and values and flexible working

Helen Brockbank Executive Assistant and Office Manager

I love working at Evox because I thoroughly enjoy the innovation process in a supportive and challenging environment

Justin Hean Principal Scientist

I love working at Evox because of the open and honest communication, and the opportunities for career advancement within a diverse culture

Tracey Richardson Talent Acquisition Partner

Oxford

Evox Therapeutics
OX4 4HG Oxford Directions careers@evoxtherapeutics.com +44 (0)1865 819140 View page

Already working at Evox Therapeutics?

Let’s recruit together and find your next colleague.

email
@evoxtherapeutics.com
Teamtailor

Career site by Teamtailor